Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | -1.34% | -3.61% | +17.60% |
Dec. 06 | Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays | CI |
Nov. 09 | Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating | MT |
Financials (USD)
Sales 2023 * | 1.51M | Sales 2024 * | 2.48M | Capitalization | 24.62M |
---|---|---|---|---|---|
Net income 2023 * | -20M | Net income 2024 * | -24M | EV / Sales 2023 * | 16.3 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 9.94 x |
P/E ratio 2023 * |
-1.19
x | P/E ratio 2024 * |
-1.04
x | Employees | 76 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 94.23% |
Latest transcript on OncoCyte Corporation
1 day | -0.34% | ||
1 week | -3.61% | ||
Current month | +1.03% | ||
1 month | -0.68% | ||
3 months | +17.60% | ||
6 months | -8.12% | ||
Current year | +17.60% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Riggs
CEO | Chief Executive Officer | 42 | 20-07-31 |
James Liu
DFI | Director of Finance/CFO | 29 | 21-06-30 |
Yuh-Min Chiang
CTO | Chief Tech/Sci/R&D Officer | - | 21-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Last
BRD | Director/Board Member | 64 | 15-12-22 |
Alfred Kingsley
BRD | Director/Board Member | 81 | 09-08-31 |
Louis Silverman
BRD | Director/Board Member | 65 | 22-11-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.94 | -1.34% | 17 061 |
24-03-27 | 2.98 | -0.60% | 1,766 |
24-03-26 | 2.998 | -0.68% | 11,395 |
24-03-25 | 3.018 | -1.36% | 1,780 |
24-03-22 | 3.06 | +0.33% | 2,519 |
Delayed Quote Nasdaq, March 28, 2024 at 02:53 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.60% | 24.62M | |
+3.04% | 108B | |
+10.05% | 104B | |
+6.58% | 23.66B | |
-12.39% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.20% | 16.19B | |
+4.85% | 13.72B | |
+34.76% | 12.22B |